Should we put angiotensin- converting enzyme inhibitors in the water supply? Joseph S. Alpert Editor’s Commentary Pages: 249 - 250
The role of pharmacotherapy and catheter-based intervention in the management of patients with non-st-segment elevation acute coronary syndromes William E. Boden OriginalPaper Pages: 260 - 271
Choice of agents to limit the coagulation cascade in acute coronary syndromes Richard C. Becker OriginalPaper Pages: 272 - 277
The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease James S. ZebrackJeffrey L. Anderson OriginalPaper Pages: 278 - 288
Early use of statins in acute coronary syndromes Joshua M. SpinRandall H. Vagelos OriginalPaper Pages: 289 - 297
Glycoprotein receptor inhibitors in the management of acute coronary syndromes Henock Saint-JacquesRobert A. Harrington OriginalPaper Pages: 301 - 312
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction Ara M. MaranianSteven R. Steinhubl OriginalPaper Pages: 313 - 319
Lipid-lowering therapies in the management of acute coronary syndromes Lori MoscaAngelo Biviano OriginalPaper Pages: 320 - 326
Unfractionated versus fractionated heparin for percutaneous coronary intervention Heidar ArjomandSatish K. SurabhiMarc Cohen OriginalPaper Pages: 327 - 333
Early invasive strategies for acute coronary syndromes Martin J. QuinnSorin J. Brener OriginalPaper Pages: 334 - 340
New biomarkers in the risk stratification of patients with suspected acute myocardial infarction Bret A. RogersL. Kristin Newby OriginalPaper Pages: 341 - 347